Skip to Content Facebook Feature Image

KKR Invests in Stockholm Multifamily Housing Development Led by Reliwe and Derome

News

KKR Invests in Stockholm Multifamily Housing Development Led by Reliwe and Derome
News

News

KKR Invests in Stockholm Multifamily Housing Development Led by Reliwe and Derome

2025-02-21 15:10 Last Updated At:15:21

STOCKHOLM--(BUSINESS WIRE)--Feb 21, 2025--

Global investment firm KKR today announced the agreement with leading Swedish developers Reliwe and The Derome Group for the forward-purchase of three multifamily properties currently under development in Haninge, located just south of the Stockholm city center. The investment is being made by KKR's European Real Estate strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220298047/en/

The development is comprised of three new properties totaling 382 residential units, expected to be completed between late 2026 and early 2027. Leading Swedish property developer Reliwe is overseeing the development, which includes two timber construction properties being built by Derome, a leading industrial business, and a third traditional concrete construction asset built to a high specification. The development is located adjacent to a bus terminal and railway station, offering excellent connectivity to Stockholm’s city center. The project is designed to meet high environmental standards and will deliver affordable modern urban living space with premium amenities and features.

"We are thrilled to make our first residential investment in Stockholm, which is an attractive market where we are seeing strong momentum towards our objective of building a portfolio of residential units by partnering with best-in-class partners such as Reliwe and Derome,” said Alexander Thams, Head of Nordics Real Estate for KKR. "This development exemplifies the type of high-quality, sustainable residential properties we aim to invest in. With Stockholm's strong residential market fundamentals and the innovative use of timber construction, we see significant potential to deliver value to our investors while contributing positively to the community."

"KKR’s decision to make this their first residential investment in Stockholm alongside us is a strong endorsement of what we have built and the innovation we continue to bring to the Swedish residential market. We look forward to delivering high-quality, sustainable residential properties. Central Haninge is a prime growth location, and we see significant potential in developing attractive apartments,” says Gurmo Endale, Partner at Reliwe.

"We are pleased to partner with Reliwe in this transaction with a leading industry player, KKR. Together, we look forward to completing this unique development with a significant share of timber construction, which contributes to sustainability. We are proud that KKR has chosen to invest in timber – a modern and environmentally responsible building solution with long-term benefits," says Otto Martler, CEO for Derome BoPartner.

KKR will be working with local operating partner Cavendo on managing and growing the Stockholm residential platform. Roschier, Svalner, Red Management and Tango Capital Markets served as advisors on the transaction.

Over the past two years, KKR has committed approximately $550 million (SEK 6 billion) to its Nordics real estate investments, focusing on acquiring high-quality residential and logistics assets and transacting with strategic local counterparties. KKR’s global real estate business invests thematically in high-quality real estate through a full range of scaled equity and debt strategies. KKR’s more than 140 dedicated real estate investment and asset management professionals across 16 offices apply the capabilities and knowledge of KKR’s global platform to deliver outcomes for clients and investors.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Reliwe

Reliwe is an expansive real estate development company focusing on sustainability and design to create residences to thrive in. Since its establishment, Reliwe has completed over 500 apartments and has 1,550 apartments in production. In addition, the company has made substantial acquisitions of building rights in various cities across Sweden. Reliwe is actively expanding its presence in the Swedish real estate market and is dedicated to developing well designed residential properties. For additional information about Reliwe, please visit Reliwe’s website at www.reliwe.se.

About Derome

Derome is Sweden's largest family-owned wood industry, managing the entire value chain from forest to finished house. We simplify the customer's life and promote sustainable development through forest refinement, wood production and sales, construction and industrial products, equipment rental, construction logistics, and residential development. For additional information about Derome, please visit Derome’s website at www.derome.se.

Credit: Reliwe / Lindberg Stenberg Arkitekter AB

Credit: Reliwe / Lindberg Stenberg Arkitekter AB

NEWARK, Del.--(BUSINESS WIRE)--Jan 15, 2026--

QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/

The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements.

“Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Derek Grimes, Executive Vice President of QPS. “Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customer’s clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”

“Oracle Argus provides QPS Holdings, LLC with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations, while streamlining end-to-end safety operations and insights at scale,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our industry-leading solutions, QPS Holdings, LLC can further transform and elevate its safety case management for customers worldwide.”

The deployment of Oracle Argus will enable QPS to:

As the demand for innovative therapies continues to rise, CROs play a critical role in managing both development speed and patient safety. By leveraging the Oracle Argus platform, QPS is well-positioned to deliver on its mission to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services.

###

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. For more information, visit http://www.qps.com or email info@qps.com.

ABOUT ORACLE ARGUS

Oracle Argus is an industry-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in pre-market and post-market drugs, biologics, vaccines, devices, and combination products. Oracle has been a Leader in the IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services 2025 Vendor Assessment (doc # US53669225, July 2025). To learn more about Oracle’s pharmacovigilance portfolio visit: https://www.oracle.com/life-sciences/safety-solutions/argus-safety-case-management/. Trademarks: Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation.

Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.

Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.

Recommended Articles